NasdaqGS:MGNX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. More Details


Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has MacroGenics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MGNX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-9.5%

MGNX

-2.7%

US Biotechs

-0.4%

US Market


1 Year Return

153.6%

MGNX

33.6%

US Biotechs

18.3%

US Market

Return vs Industry: MGNX exceeded the US Biotechs industry which returned 33.6% over the past year.

Return vs Market: MGNX exceeded the US Market which returned 18.3% over the past year.


Shareholder returns

MGNXIndustryMarket
7 Day-9.5%-2.7%-0.4%
30 Day-11.7%2.7%6.6%
90 Day-16.1%-3.0%8.6%
1 Year153.6%153.6%35.9%33.6%21.0%18.3%
3 Year13.6%13.6%20.0%13.9%42.1%32.7%
5 Year-28.9%-28.9%14.5%6.2%85.6%64.7%

Price Volatility Vs. Market

How volatile is MacroGenics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MacroGenics undervalued compared to its fair value and its price relative to the market?

4.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MGNX ($22.09) is trading above our estimate of fair value ($0.88)

Significantly Below Fair Value: MGNX is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MGNX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MGNX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MGNX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MGNX is overvalued based on its PB Ratio (4.8x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

14.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MGNX's revenue (30.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MGNX's revenue (30.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MGNX is forecast to be unprofitable in 3 years.


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has MacroGenics performed over the past 5 years?

-33.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MGNX is currently unprofitable.

Growing Profit Margin: MGNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MGNX is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.

Accelerating Growth: Unable to compare MGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: MGNX has a negative Return on Equity (-67.25%), as it is currently unprofitable.


Next Steps

Financial Health

How is MacroGenics's financial position?


Financial Position Analysis

Short Term Liabilities: MGNX's short term assets ($260.2M) exceed its short term liabilities ($45.9M).

Long Term Liabilities: MGNX's short term assets ($260.2M) exceed its long term liabilities ($33.9M).


Debt to Equity History and Analysis

Debt Level: MGNX is debt free.

Reducing Debt: MGNX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MGNX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is MacroGenics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MGNX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Scott Koenig (68 yo)

19.08yrs

Tenure

US$4,723,588

Compensation

Dr. Scott Koenig, M.D., Ph.D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics. He served as Senior Vice President of R ...


CEO Compensation Analysis

Compensation vs Market: Scott's total compensation ($USD4.72M) is above average for companies of similar size in the US market ($USD2.94M).

Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Scott Koenig
CEO, President & Director19.08yrsUS$4.72m2.15%
$ 25.7m
James Karrels
Senior VP12.42yrsUS$1.78m0.28%
$ 3.4m
Ezio Bonvini
Senior VP of Research & Chief Scientific Officer4.08yrsUS$1.90m0.17%
$ 2.0m
Eric Risser
Senior VP of Business Development & Portfolio Management and Chief Business Officer4.08yrsUS$1.78m0.082%
$ 982.3k
Anna Krassowska
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Jeffrey Peters
VP & General Counsel3.33yrsno data0%
$ 0
Thomas Spitznagel
Senior Vice President of BioPharmaceutical Development & Manufacturingno datano datano data
Stephen Eck
Senior VP of Clinical Development & Chief Medical Officer0.25yrno datano data
Lynn Cilinski
VP, Controller & Treasurer17yrsno datano data

4.1yrs

Average Tenure

57.5yo

Average Age

Experienced Management: MGNX's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Scott Koenig
CEO, President & Director19.08yrsUS$4.72m2.15%
$ 25.7m
David Stump
Independent Director7.08yrsUS$176.53k0%
$ 0
Edward Hurwitz
Independent Director16yrsUS$171.50k0.033%
$ 399.3k
Kenneth Galbraith
Independent Director12.25yrsUS$187.47k0%
$ 0
Paulo Costa
Independent Chairman of the Board7.08yrsUS$210.46k0.11%
$ 1.3m
Scott Jackson
Independent Director3.75yrsUS$175.47k0%
$ 0
Jay Siegel
Independent Director2.92yrsUS$180.12k0%
$ 0
Karen Jean Ferrante
Independent Director3.75yrsUS$176.53k0%
$ 0

7.1yrs

Average Tenure

64.5yo

Average Age

Experienced Board: MGNX's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.7%.


Top Shareholders

Company Information

MacroGenics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MacroGenics, Inc.
  • Ticker: MGNX
  • Exchange: NasdaqGS
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.195b
  • Shares outstanding: 54.12m
  • Website: https://www.macrogenics.com

Number of Employees


Location

  • MacroGenics, Inc.
  • 9704 Medical Center Drive
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MGNXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2013
M55DB (Deutsche Boerse AG)YesCommon StockDEEUROct 2013

Biography

MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates inclu ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/25 00:32
End of Day Share Price2020/10/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.